┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0120
  SLUG ................ /study-329-regulatory-journal-policy-changes
  STATUS .............. ACTIVE
  FILED ............... 2026-06-15 08:49 UTC
  LAST ANNOTATED ...... 2026-06-15 08:49 UTC
  CLAIMS ON FILE ...... 6
  MEAN TAG CONFIDENCE . 0.95
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Study 329: Regulatory and Journal Policy Changes on Trial Registration and Data Sharing

SUMMARY

The clinical trial Study 329, involving the antidepressant paroxetine, has been a focal point for discussions around data transparency and publication ethics. The trial's original 2001 publication claimed efficacy and safety for paroxetine in adolescent depression, a finding later challenged by re-analyses of the raw data that demonstrated a lack of efficacy and increased harms. This controversy spurred renewed calls for greater transparency in clinical trial data and reporting.

In response to broader concerns about data integrity and accessibility, regulatory bodies and medical journals have introduced new policies concerning trial registration and data sharing. The International Committee of Medical Journal Editors (ICMJE) requires clinical trial registration as a condition for publication, a policy followed by over 1,000 journals. Additionally, the ICMJE recommends that data-sharing plans be declared at registration and updated if changes occur. However, it remains an open question whether these changes were directly and solely a result of Study 329, or part of a larger, evolving movement towards clinical trial transparency.

STRONGEST CASE FOR

The controversy surrounding Study 329, particularly the re-analysis revealing suppressed negative data, significantly highlighted the critical need for independent access to raw clinical trial data. This event served as a powerful catalyst, demonstrating how inadequate transparency could mislead medical practice and harm patients. Consequently, it put immense pressure on regulatory bodies and journals to implement more stringent trial registration and data-sharing policies to prevent similar occurrences and ensure public health is prioritized over commercial interests.

STRONGEST CASE AGAINST

While Study 329 certainly contributed to the broader discussion on clinical trial transparency, it was one of many instances that collectively underscored the need for reform. The movement towards trial registration and data sharing was already gaining momentum prior to and independent of Study 329, driven by various stakeholders, including patient advocates, academics, and other high-profile cases of publication bias. Therefore, attributing specific policy changes solely to Study 329 oversimplifies a complex and multifactorial evolution in medical research ethics and regulation.

CLAIMS

  1. VERIFIEDCONF 1.00

    The International Committee of Medical Journal Editors (ICMJE) implemented a clinical trial registration policy.

    — attributed to: ICMJE

    • https://clinicaltrials.gov/policy/reporting-requirements
    • https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html
  2. VERIFIEDCONF 1.00

    The ICMJE policy on trial registration is followed by more than 1,000 journals.

    — attributed to: ClinicalTrials.gov

    • https://clinicaltrials.gov/policy/reporting-requirements
  3. VERIFIEDCONF 1.00

    The ICMJE recommends that changes to a data sharing plan after trial registration should be reflected in the manuscript and registry record.

    — attributed to: ICMJE

    • https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html
  4. CORROBORATEDCONF 0.90

    Existing regulatory frameworks and policies govern clinical trial data sharing.

    — attributed to: A published scientific review

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC9118011/
  5. VERIFIEDCONF 1.00

    The European Union requires all clinical trial submissions, including site information, to be done by or on behalf of the sponsor.

    — attributed to: European Commission

    • https://health.ec.europa.eu/document/download/bd165522-8acf-433a-9ab1-d7dceae58112_en
  6. CORROBORATEDCONF 0.80

    Policies governing the sharing of clinical trial data are discussed in both published articles and grey literature (non-peer-reviewed publications).

    — attributed to: A scientific review methodology

    • https://www.sciencedirect.com/science/article/pii/S089543562200289X

TIMELINE

  • 2001Original publication of Study 329 in the Journal of the American Academy of Psychiatry and the Child.
  • 2004ICMJE updates its recommendations to require trial registration as a condition for publication. [src]
  • 2010sIncreased scrutiny and re-analysis of Study 329 data reveals misrepresentation of results.
  • 2020 Jan 22Publication summarizing experience with digital sharing of clinical trial data, focusing on methods and stages. [src]

ENTITIES

  • ORG International Committee of Medical Journal Editors (ICMJE) — Influential medical journal policy-setting body
  • EVENT Study 329 — Clinical trial for paroxetine in adolescents
  • ORG European Union (EU) — Regulatory body
  • ORG ClinicalTrials.gov — Clinical trial registry

OPEN QUESTIONS — PENDING LEADS

  • What specific regulatory guidance or policy documents were issued by the FDA or EMA directly referencing Study 329 as a justification for new data sharing requirements?
  • Which major medical journals explicitly cited Study 329 when announcing or modifying their trial registration or data-sharing policies?
  • Are there official statements from the ICMJE or similar bodies that specifically link the controversies of Study 329 to the timing or content of their data sharing recommendations?
  • What was the timeline of key policy changes regarding trial registration and data sharing prior to and immediately following the re-analysis of Study 329 data?
  • Did any pharmaceutical industry bodies (e.g., PhRMA) issue new guidelines on data transparency in direct response to the scrutiny faced by GlaxoSmithKline regarding Study 329?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://freidok.uni-freiburg.de/files/221245/UrDgfvM9xUOKLrXR/e049228.full.pdf
    ABSTRACT. Objectives To explore the impact of data- sharing initiatives on the intent to share data, on actual data sharing, on the use of shared data and ...
  2. [REDDIT] https://www.reddit.com/r/BattleBitRemastered/
    14 Apr 2021 · I went to the Battlebit website and submitted a request to have the ban reviewed via the anti-cheat system. It was just that my friends were ...
  3. [REDDIT] https://www.reddit.com/r/linux_gaming/comments/r1atff/i_think_what_linus_and_luke_at_ltt_are_doing_is/ [archived]
    24 Nov 2021 · It's mostly been ceremonial and surface level changes IMO, but maybe I've missed some technical discussions of serious changes distributions/ ...
  4. [REDDIT] https://www.reddit.com/r/WritingPrompts/comments/3uuym4/wp_soul_mates_are_real_and_technology_has_finally/ [archived]
    30 Nov 2015 · Soul mates are real and technology has finally allowed for detection of some peoples “other half" at the speed of light using quantum messaging.
  5. [WEB] https://health.ec.europa.eu/document/download/bd165522-8acf-433a-9ab1-d7dceae58112_en
    Answer: In the EU, all submissions concerning a clinical trial, including information on the clinical trial sites, are done by or on behalf of the sponsor (and.
  6. [WEB] https://clinicaltrials.gov/policy/reporting-requirements
    ICMJE issued a clinical trial registration policy as part of the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, which is followed by more than 1,000 journals.
  7. [WEB] https://www.intechopen.com/chapters/71067 [archived]
    22 Jan 2020 · This chapter summarises the experience with the digital sharing of clinical trial data, focusing on the methods and stages of data sharing.
  8. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC9118011/ [archived]
    Objective This review seeks to identify regulatory frameworks and policies that govern clinical trial data sharing and explore key elements of data-sharing mechanisms as outlined in existing regulatory documents. Following from, and based on, this empirical analysis of gaps in ex…
  9. [WEB] https://ses.library.usyd.edu.au/bitstream/handle/2123/25685/jrsm.1500.pdf?sequence=1&isAllowed=y [archived]
    The primary objec- tives of this study were to determine IPD sharing plans reported in recently registered clinical trial registration records, how data sharing ...
  10. [WEB] https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html [archived]
    The ICMJE's policy regarding trial registration is explained above. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.
  11. [REDDIT] https://www.reddit.com/r/germany/comments/pdfqfr/is_iu_international_university_of_applied/ [archived]
    28 Aug 2021 · Hello , I'm from Italy and thinking of taking the Computer Science undergrad with the University of Applied Sciences in Germany (online ...
  12. [REDDIT] https://www.reddit.com/r/ChatGPT/comments/1gzkfrk/just_bought_the_plus_subscription_now_what_do_i/ [archived]
    25 Nov 2024 · I use public GPTs for clients and upload their business info so frontend users can ask it questions about the business. I have a dozen private ...
  13. [WEB] https://www.sciencedirect.com/science/article/pii/S089543562200289X
    Two searches were conducted, a bibliographic search for published articles that present beliefs, opinions, similarities, and differences regarding policies governing the sharing of clinical trial data. The second search analyzed the gray literature (non-peer-reviewed publications…
  14. [REDDIT] https://www.reddit.com/r/AskHistorians/comments/13zjyot/historians_what_do_you_think_is_currently_the/ [archived]
    3 Jun 2023 · Historians, what do you think is currently the single most controversial or debated topic in your specific area of study, and what is it about?
  15. [REDDIT] https://www.reddit.com/r/sysadmin/comments/1h2gbft/what_was_the_most_challenging_issue_you_solved/
    29 Nov 2024 · Curious, from an IT standpoint, the trials and tribulations others have dealt with. I always take pride in solving issues.
  16. [REDDIT] https://www.reddit.com/r/labrats/comments/1iq1wsy/if_the_nih_is_reduced_damaged_or_dismantled_how/ [archived]
    15 Feb 2025 · Suppose that the 15% overhead policy sticks and that there are other big changes to the NIH mission with big budget reductions.

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Medical Writing Support Disclosure Guidelines for IRBs and Journals (1994-2001) — SHARES-ACTOR (INCOMING)MEDICAL WRITING SUPPORT D…Study 329: Regulatory and Journal Policy Changes on Trial Registration and Data SharingSTUDY 329: REGULATORY AND J…THIS FILESHARES-EVENTSHARES-ACTOR